Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France
Year: 2025
Type: article
Study design: Observational Study
Abstract: AIM: Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France. PATIENTS & METHODS: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database. RESULTS: Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012. CONCLUSION: The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.
Source: Future Oncology
Authors: Florence Joly, Stephane Culine, Morgan Roupret, Aurore Tricotel, Emilie Casarotto, Sandrine Brice, Rafael Minacori, Marthe Vuillet, Marie-Catherine Thomas, Kirsten Leyland, Anil Upadhyay, Vicki Munro, Torsten Strunz-McKendry
Institutions: Inserm, Normandie Université, Centre Hospitalier Universitaire de Caen Normandie, Centre François Baclesse, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers, Université de Caen Normandie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Sorbonne Université, IQVIA (United Kingdom), Astellas Pharma (United Kingdom)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Pfizer, Seagen, Astellas Pharma
OpenAlex ID: W4407795613